Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Letter Regarding Texas Senate Bill 754 (2019) – Requesting Amendments
-
ACMG Comments to Congress Concerning the Verifying Accurate Leading-edge IVCT Development (VALID) Act Discussion Draft
-
ACMG Letter to Congress Regarding the Advancing Access to Precision Medicine Act
-
ACMG Letter Regarding Pennsylvania House Bills 2618 and 2619 (2018) – Requesting Amendments
-
ACMG Letter Regarding Pennsylvania Senate Bills 1074 and 1169 (2018) – Requesting Amendments
-
Group Sign-on Letter to CMS Supporting CY 2019 PFS Changes to Reduce E/M Documentation Burden
-
ACMG Letter to Congress Concerning the FDA Technical Assistance for the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Comments to CMS Concerning CLFS Gapfill Preliminary Determinations for GS Codes 81425, 81426, and 81427
-
Group Sign-on Letter to Congress Concerning the Diagnostic Accuracy and Innovation Act (DAIA)
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations